rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Dhiraj H. Malkani

Chief Strategy Officer

Company insider

Files Form 4 as: Chief Strategy Officer, Kiniksa Pharmaceuticals International.

In numbers

Trades disclosed
12
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
1
Companies where not an officer
0
First trade
1 Jul 2026
Last trade
1 Jul 2026
Last filed
6 Jul 2026

Companies traded

Where they are an officer
KNSA Kiniksa Pharmaceuticals InternationalOfficer · Biotechnology · last 1 Jul 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—82,600 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—14,000 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—2,119 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—82,600 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—14,000 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—2,119 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—2,188 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—1,245 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—1,307 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—2,188 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—1,245 at $0.00filing
1 Jul 2026filed 6 Jul 2026KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · BiotechnologySEC FORM 4 Code A—1,307 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Michael R. MegnaChief Accounting Officer · Chief Accounting Officer at Kiniksa Pharmaceuticals International, filing Form 4 there in the last year
Mark RagosaChief Financial Officer · Chief Financial Officer at Kiniksa Pharmaceuticals International, filing Form 4 there in the last year
Ross MoatChief Operating Officer · Chief Operating Officer at Kiniksa Pharmaceuticals International, filing Form 4 there in the last year
Sanj K. PatelChairman & CEO · Chairman & CEO at Kiniksa Pharmaceuticals International, filing Form 4 there in the last year
John F. PaoliniChief Medical Officer · Chief Medical Officer at Kiniksa Pharmaceuticals International, filing Form 4 there in the last year